Administration of MRX1, in a study run in partnership with Robert Gordon University, has shown significant cardioprotective effects in a mouse study, demonstrating its potential as a treatment for patients with heart failure with preserved ejection fraction (HFpEF).

Cardiac fibrosis is a condition characterized by the thickening and stiffening of the heart tissue, often leading to impaired heart function. HFpEF, accounting for 50% of heart failure cases, presents as clinical heart failure symptoms with a normal ejection fraction. This condition's incidence is rising with the aging population and the increasing prevalence of comorbidities, making it a critical unmet need in cardiology.